Insight

Itai Yanai: Reflections on Advances in Cancer Research in 2024

med.nyu.edu

Dec 4, 2024, 19:07

Itai Yanai: Reflections on Advances in Cancer Research in 2024

Itai Yanai, Professor in the Department of Biochemistry and Molecular Pharmacology at NYU Langone Health, shared a post on X about a recent paper by him and colleagues published in Cancer Discovery:

“Reflections on Advances in Cancer Research in 2024”

Authors: Katherine Aird, Aadel Chaudhuri, Jennifer Guerriero, Shiri Gur-Cohen, Benjamin Izar, Brittany Jenkins, Delphine Merino, Alejo Rodriguez-Fraticelli, Shensi Shen, Itai Yanai.

“Out today! What were some of the most inspiring cancer papers of 2024?

Cancer Discovery asked me, Katherine Aird, Aadel Chaudhuri, Jennifer Guerriero, Shiri Gur-Cohen, Benjamin Izar, Brittany Jenkins, Delphine Merino, Alejo Rodriguez-Fraticelli and Shensi Shen.”

Aadel Chaudhuri, Vice Chair of Translational Research in the Department of Radiation Oncology at Mayo Clinic, shared this post, adding:

“Really nice piece put together by Cancer Discovery summarizing some of the most inspiring cancer papers of 2024.

Grateful to co-author this piece with a group of gifted cancer researchers from across the land.”

Elizabeth McKenna, Executive Director of Cancer Discovery at AACR, shared these posts too:

“Thank you Aadel Chaudhuri for sharing your thoughts in this piece!”

More posts featuring Itai Yanai.

Itai Yanai is a Professor in the Department of Biochemistry and Molecular Pharmacology at NYU Langone Health. Previously he served as the Assistant and Associate Professor in the Department of Biology at Israel Institute of Technology. He was also a research assistant at Pasteur Institute.

Aadel Chaudhuri, MD PhD is the Vice Chair of Translational Research in the Department of Radiation Oncology at Mayo Clinic. He is also a Visiting Associate Professor, in the Department of Computer Science and Engineering at the Washington University in St. Louis.

His research focuses on the development and application of biofluid-based cell-free DNA technologies for solid tumor response assessment and molecular residual disease (MRD) detection.

Elizabeth McKenna is the Executive Director of Cancer Discovery at the American Association for Cancer Research. Elizabeth earned her PhD from Harvard University and trained with Dr. Charles Roberts at the Dana-Farber Cancer Institute.

Her research was among the first to show that pediatric tumors characterized by mutations in chromatin remodelers are genomically stable and instead driven by epigenetic deregulation of key target genes.

She joined Cancer Discovery shortly after its launch as its founding Science Writer and became an editor in 2014, rising through the editorial ranks to become the journal’s Executive Editor in 2019. She is a member of the 40 Under 40 in Cancer Class of 2021.